NCT06985758 - Pharmacokinetic Study of Rezafungin in Patients With Suspected Intra-Abdominal Candidiasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

January 31, 2026

Conditions

Candidal Peritonitis

Interventions

DRUG

Rezafungin 400mg followed by weekly doses of intravenous Rezafungin 200mg

Intravenous administration of a first dose of Rezafungin 400mg followed by weekly doses of intravenous Rezafungin 200mg to study the pharmacokinetic parameters of the drug.

Trial Locations (3)

28034

Hospital Universitario Ramón y Cajal, Madrid

28046

Hospital Universitario La Paz, Madrid

46010

Hospital Clínico Universitario de Valencia, Valencia

All Listed Sponsors

lead

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

OTHER